CLINDESSE Drug Patent Profile

When do Clindesse patents expire, and when can generic versions of Clindesse launch?

Clindesse is a drug marketed by Padagis Us and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in fourteen countries.

The generic ingredient in CLINDESSE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clindesse

A generic version of CLINDESSE was approved as clindamycin phosphate by HIKMA on April 25^th, 1988.

Summary for CLINDESSE

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	1
Patent Applications:	2,857
Drug Prices:	Drug price information for CLINDESSE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CLINDESSE
What excipients (inactive ingredients) are in CLINDESSE?	CLINDESSE excipients list
DailyMed Link:	CLINDESSE at DailyMed

See drug prices for CLINDESSE

See drug sales revenues for CLINDESSE

Recent Clinical Trials for CLINDESSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Watson Laboratories, Inc.	Phase 3
Actavis Inc.	Phase 3

See all CLINDESSE clinical trials

Pharmacology for CLINDESSE

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

Paragraph IV (Patent) Challenges for CLINDESSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CLINDESSE	Vaginal Cream	clindamycin phosphate	2%	050793	1	2015-02-05

US Patents and Regulatory Information for CLINDESSE

CLINDESSE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004		RX	Yes	Yes			Y

Expired US Patents for CLINDESSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004
Padagis Us	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004

International Patents for CLINDESSE

See the table below for patents covering CLINDESSE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	68686
Canada	1338977	SYSTEMES D'ADMINISTRATION VAGINALE (VAGINAL DELIVERY SYSTEMS)
Germany	3584523
European Patent Office	0244405	VAGINAL DELIVERY SYSTEMS
Japan	2519029
Japan	S63501563
World Intellectual Property Organization (WIPO)	8702576

Supplementary Protection Certificates for CLINDESSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	92401	Luxembourg		PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
1304992	CR 2013 00053	Denmark		PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992	PA2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992	2013/044	Ireland		PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
1304992	C01304992/01	Switzerland		PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1304992	122013000081	Germany		PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322

CLINDESSE (clindamycin phosphate) market dynamics and financial trajectory: exclusivity, competition, and revenue exposure

Last updated: July 22, 2026

Executive summary: CLINDESSE (clindamycin phosphate) vaginal cream 2% is a long-tenured branded product with a largely matured US competitive landscape. The market is characterized by (1) constrained replacement cycles typical of prescription women’s health topical therapy, (2) price erosion driven by generic and therapeutic alternatives, and (3) limited ability for the brand to defend share once formulary access shifts and pricing pressure increases. By design, CLINDESSE is not a high-barrier “evergreen” platform product; it competes in a narrow clinical segment against other intravaginal antibacterials and against systemic clindamycin regimens. The financial trajectory is therefore tied to generic substitution dynamics, payer formulary behavior, and prescriber switching rather than to large new-label expansions.

---

What is CLINDESSE and what market segment does it serve?

CLINDESSE is an intravaginal clindamycin phosphate cream indicated for bacterial vaginosis (BV). It is a branded, prescription women’s health topical antibiotic product used as an alternative to oral metronidazole and other intravaginal agents.

Where does CLINDESSE sit in BV treatment algorithms?

BV prescribing typically follows:

• first-line or commonly used intravaginal agents (including metronidazole products) and oral metronidazole in many guidelines
• patient-specific selection based on tolerability, prior response, and contraindications
• short-course topical delivery when patients prefer local therapy or when oral therapy is less tolerated

CLINDESSE’s market role is narrow and dependent on:

• guideline adherence and local prescribing norms
• payer formulary placement and prior authorization requirements
• substitution by lower-priced generic topical clindamycin products and therapeutic equivalents

---

How does CLINDESSE compete against metronidazole and other BV therapies?

CLINDESSE competes primarily on:

• clinical fit for BV treatment
• local tolerability profile
• payer preference for low-cost options

Key competitive axes

1. Formulary positioning
   • Brands lose share when formulary tiers shift to cheaper generics or preferred intravaginal metronidazole.
2. Price and net revenue
   • Even modest list-price pressure can materially reduce net sales once rebates and discounts are recalculated by large payers.
3. Prescriber switching
   • BV is routine care; when payers steer to alternatives, switching occurs quickly without long therapeutic ramp-up.

Substitution risk

Topical antibiotics for BV generally face:

• high substitution once generics are available
• short switching friction because the indication is consistent and courses are brief

---

When does CLINDESSE lose exclusivity in the US and what does that imply for sales?

CLINDESSE is a legacy branded product, so its exclusivity window has long since matured. The financial model for such products is dominated by:

• generic launches (ANDA or switchovers)
• formulary reranking
• margin compression as net prices decline

Exclusivity-driven sales impact

Once exclusivity ends, the sales curve typically shifts from:

• branded share stability with discounting to
• sustained erosion driven by generic penetration and competitive contracting

For CLINDESSE, this means the “growth” path is structurally limited. The likely post-exclusivity financial trajectory is:

• steady volume decline and/or
• rapid net price erosion as contracts move to generic or preferred therapeutics

---

How many patents protect CLINDESSE and what is the patent estate strength?

For CLINDESSE, the patent estate is mature and largely determines only residual barriers such as:

• method-of-use refinements
• formulation-specific protection (if still active in relevant jurisdictions)
• manufacturing process IP (if not designed around by competitors)

In a mature branded topical product category, estate strength is usually evaluated by:

• whether multiple independently enforceable claims remain active
• whether ANDA entrants face meaningful litigation risk for specific claim sets
• whether formulation/process claims create production or quality system barriers

What typically matters for topical antibiotic products

• formulation patents that control cream properties and stability
• process claims for manufacturing controls
• use patents that are narrower than the label (less protective than formulation/process claims)

---

What is the Orange Book status of CLINDESSE, and does it show active listings?

CLINDESSE’s US regulatory landscape is best interpreted via:

• Orange Book “active” listings (drug product and patent expiration)
• linkage to approved application(s)
• whether listed patents are tied to the NDA drug substance/drug product or additional exclusivity

Given the product’s legacy positioning, the Orange Book status likely reflects:

• predominantly expired or near-expired protections for core drug product claims
• any remaining active listings that could be targeted by generic applicants via carve-outs or design-arounds

---

What generic entry risks exist for CLINDESSE?

Key generic entry risks include:

• formulation or manufacturing design-around feasibility
• ability to meet bioequivalence for topical vaginal products
• any remaining enforceable patents on formulation attributes or process controls

Practical reality in women’s health topical antibiotics

Because BV courses are short and the competitive set is broad, generic entrants typically gain share quickly after launch if:

• formulary and pharmacy benefit manager (PBM) contracts align with the lowest-cost option
• prescribers accept the substitution due to consistent indication and dose form

---

What patent litigation affects CLINDESSE and how does it influence launch timing?

For legacy topical products, patent litigation usually affects:

• the timing of first generic launch
• the duration of “at-risk” launches
• settlement terms that may include “launch calendars,” partial take-backs, or non-monetary agreements

The financial implication is that sustained branded revenue depends less on ongoing injunction threats and more on:

• whether litigation blocked or delayed the first effective generic competitors
• whether later entrants faced additional barriers

---

What are the most important US regulatory milestones for CLINDESSE’s competitive trajectory?

Regulatory milestones shape competition through:

• approval of generics or authorized equivalents
• labeling changes that affect substitutability
• updates that alter REMS requirements (if any), warnings, or contraindications (usually less relevant for established products)

For CLINDESSE, competition is mainly driven by:

• ANDA approvals and market entry
• labeling parity that supports easy pharmacy substitution

---

What is the financial trajectory for CLINDESSE: sales drivers and headwinds?

CLINDESSE’s financial trajectory in a mature market is typically governed by four measurable drivers:

1. Net price compression

   • Generic substitution shifts pricing power quickly to competitors with lower WAC and negotiated net pricing.

2. Volume erosion

   • Prescription share migrates to preferred agents within the PBM formulary network.

3. Payer contract dynamics

   • Rebate levels and tier status can accelerate erosion even after generic availability stabilizes.

4. Demand stability of BV treatment

   • BV prevalence sustains baseline prescriptions, but product-level share declines as alternatives compete on cost.

Implications for revenue exposure

• Branded revenue is likely concentrated in periods immediately after formulary access changes and before full generic penetration.
• Once multiple cheaper alternatives exist, CLINDESSE’s net revenue becomes increasingly sensitive to:
  • contract renegotiations
  • shifts in preferred intravaginal therapy lists
  • physician switching patterns

---

How do net sales typically evolve for mature branded topical antibiotics like CLINDESSE?

A mature branded topical drug in a commoditizing class typically shows:

• plateauing or gradual decline during late-stage exclusivity
• sharper decline immediately after first generic entry
• ongoing decline at a slower pace as the market stabilizes into a preferred-contract equilibrium

The “shape” is usually less about new competitors entering late and more about:

• contract optimization by PBMs
• annual formulary refresh cycles

---

How does CLINDESSE compare with competing BV products on market dynamics?

Key comparison dimensions

• Cost position: generics and preferred alternatives tend to dominate
• Therapy choice inertia: short-course topical therapy can switch quickly
• Formulary tiering: the biggest determinant of realized revenue, not just clinical preference

Where CLINDESSE tends to underperform

• when intravaginal metronidazole or clindamycin generics become the contracted preferred option
• when formulary restrictions or prior authorization steer patients away

---

What commercial strategy levers can defend CLINDESSE share (and which are likely limited)?

For a legacy topical product, the defensible levers are limited to:

• payer-specific contracting and rebate strategy
• channel management with wholesalers and PBMs
• patient support programs (usually lower ROI once generics are preferred)
• lifecycle management around label and formulation (often constrained)

The most important lever in practice is:

• securing “preferred” status in contracted formularies, which is difficult once generics reduce payer willingness to pay.

---

Key Takeaways

• CLINDESSE operates in a narrow BV topical antibiotic segment where demand is stable but product share is highly contract-driven.
• Post-exclusivity dynamics for legacy topical antibiotics typically lead to durable net price compression and ongoing volume erosion.
• The financial trajectory is dominated by generic substitution, payer formulary reranking, and short-cycle prescriber switching rather than long-term brand differentiation.
• Litigation and patent estate details matter mainly for the timing of early generic entry; after that, market structure and PBM contracting determine the realized revenue.

---

FAQs

1) Does CLINDESSE face biosimilar-type competition?
No. CLINDESSE is a small-molecule antibiotic product, so the competitive framework is generic/ANDA substitution rather than biologics/biosimilars.

2) What changes most affect CLINDESSE net revenue: WAC or rebates?
Net revenue is typically more sensitive to payer rebates, tier placement, and formulary contracting than to small list price movements.

3) How quickly can pharmacy substitution occur after generic availability for CLINDESSE?
Substitution can occur immediately at the point of dispensing once therapeutically substitutable products are available and supported by pharmacy benefit coverage rules.

4) Does therapeutic interchange between metronidazole-based BV products and clindamycin-based therapy drive CLINDESSE share loss?
Yes. When payer formularies prefer metronidazole intravaginal options, interchange reduces CLINDESSE share even if clinical outcomes are comparable.

5) What is the primary financial risk for CLINDESSE in the remaining years of its branded life?
Incremental rebate pressure and continued formulary tier downgrades as competitors maintain lower negotiated prices.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
2. FDA Drug Approval Reports and Labeling for CLINDESSE (clindamycin phosphate) topical vaginal cream (Accessed via FDA databases).